Sino Biopharm Advances First-in-Class ROCK2 Inhibitor TDI01 Into Global First Phase III IPF Trial

Sino Biopharmaceutical ( (HK:1177) ) just unveiled an update.

Sino Biopharmaceutical has announced completion of enrollment of the first patient in a Phase III clinical trial for TDI01, its independently developed, highly selective ROCK2 inhibitor for idiopathic pulmonary fibrosis (IPF), marking the first drug of its kind worldwide to reach Phase III for this indication. The candidate has shown encouraging Phase II data, including improved lung function and a favourable safety profile versus existing standard therapies, and is also being developed for chronic graft-versus-host disease, for which it has received Breakthrough Therapy Designation in China; the advancement underscores the company’s push into first-in-class therapies targeting a large, underserved global IPF population and could strengthen its position in innovative respiratory and immunology treatments if late-stage trials are successful.

The most recent analyst rating on (HK:1177) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.

More about Sino Biopharmaceutical

Sino Biopharmaceutical Limited is a Hong Kong-listed pharmaceutical group engaged in the research, development and commercialisation of innovative drugs, with a focus on high-value therapeutic areas such as respiratory and immune-related diseases in the China and global markets.

Average Trading Volume: 76,748,870

Technical Sentiment Signal: Buy

Current Market Cap: HK$112.5B

For a thorough assessment of 1177 stock, go to TipRanks’ Stock Analysis page.